₹11 dividend and strong margins—Sun Pharma rewards investors big time

Q3 FY26 Results Snapshot - Revenue: ₹15,469 crore (↑15.1% YoY) - Net Profit: ₹3,369 crore (↑16% YoY) - EBITDA: ₹4,984 crore (↑23.4% YoY) - EBITDA Margin: 31.9% (vs. ~29% last year – expansion) - Dividend: Interim dividend of ₹11 per share; record date Feb 5, 2026, payout by Feb 16, 2026 - R&D Spend: ₹892 crore (5.8% of sales) 🌍 Segment Performance - India Formulations: ₹4,999 crore (↑16.2% YoY), market share up to 8.4%. - US Formulations: $477 million (↑0.6% YoY) – steady performance despite generic pressures. - Emerging Markets: $337 million (↑21.6% YoY). - Rest of World: $296 million (↑14.5% YoY). - Global Innovative Medicines: $423 million (↑13.2% YoY, includes $55m milestone payment). ⚠️ Investor Watchouts - Exceptional Items: ₹489 crore impact due to new labour codes. - US Business: Growth remains muted; reliance on innovative medicines offsets generic decline. - Currency & Regulatory Risks: Exposure to global markets means forex and compliance changes could affect earnings. 📈 Impact on Stock - Positive Sentiment: Strong margin expansion and dividend declaration likely to support near-term stock performance. - Medium-Term: Growth in India and emerging markets is robust, but US generics remain a drag. - Valuation: Premium justified by leadership in India and strong innovative pipeline, but investors must track US recovery. 🔮 Strategic Outlook - Growth Drivers: - Expanding innovative medicines portfolio. - Strong domestic demand and rising market share. - Emerging markets momentum. - Risks: - US generics pricing pressure. - Regulatory changes in India and abroad. - High R&D spend may weigh on short-term margins but supports long-term growth.